Stopped
AG10 · Cardiomyopathy
Trial terminated
Also in this update: Primary endpoint(s) modified; Results posted: Oct 14, 2026
Eidos Therapeutics, a BridgeBio companyPhase 2 NCT03536767 Registry history of NCT03536767 on ClinicalTrials.gov (opens the registry)